Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Companyâ€™s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
12/06/26	2.260 $	+2.26%	7,475
11/06/26	2.210 $	+12.18%	20,979
10/06/26	1.970 $	-1.01%	12,373
09/06/26	1.990 $	-0.50%	27,095
08/06/26	2.000 $	-12.28%	31,799

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			5-day change	1st Jan Change
2.260 ^USD	+2.26%		-0.88%	-30.03%

05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI
05-18	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models	RE

Market Cap	5.47M 4.73M 4.36M 4.08M 7.66M 521M 7.77M 51.66M 20.1M 253M 20.54M 20.11M 877M	P/E Ratio 2024	-0.65x	P/E Ratio 2025	-1.47x
Enterprise Value	4.09M 3.54M 3.26M 3.05M 5.72M 389M 5.81M 38.59M 15.01M 189M 15.35M 15.02M 655M	EV / Sales 2024	195,938,500x	EV / Sales 2025	1,164,761,400x
Free-Float	85.97%	Yield 2024 *	-	Yield 2025	-

05-26	Alaunos Therapeutics Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	CI
05-18	Alaunos reports preclinical ALN1003 data showing effects on insulin-resistance-related biomarkers and liver histology in diet-induced obesity models	RE
05-18	Alaunos Therapeutics Announces Updated Preclinical Data For ALN1003	CI
05-15	Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
03-31	Alaunos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-30	Alaunos Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-05	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
03-02	Alaunos Therapeutics, Inc. Announces Early Data from Two Non-Good Laboratory Practice Diet-Induced Obesity Mouse Studies Evaluating ALN1003	CI
03-02	Alaunos Therapeutics announces positive preclinical proof-of-concept data for ALN1003, a differentiated non-hormonal oral treatment for obesity and related metabolic disorders	RE
02-24	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
01-08	Alaunos Therapeutics terminates engagement with Cantor Fitzgerald	RE
12-05	Price Adrian Issues a Letter to Alaunos Therapeutics Inc	CI
11-14	Alaunos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

16/08/23	HC Wainwright Downgrades Alaunos Therapeutics to Neutral From Buy	MT
15/08/23	Laidlaw Downgrades Alaunos Therapeutics to Hold From Buy	MT
04/10/22	Wells Fargo Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
15/07/22	Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target	MT
04/05/22	Wells Fargo Upgrades Alaunos Therapeutics to Overweight From Equalweight	MT

Alaunos Therapeutics, Inc. Share Price

Stocks

TCRT

US98973P3091

Biotechnology & Medical Research

Valuation: Alaunos Therapeutics, Inc.

Chart: Alaunos Therapeutics, Inc.

Latest news : Alaunos Therapeutics, Inc.

Analysts' recommendations: Alaunos Therapeutics, Inc.

Press Releases: Alaunos Therapeutics, Inc.

News in other languages: Alaunos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Alaunos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

05-26	Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies	AQ
05-18	Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models	AQ
05-15	Ziopharm: Q1 Earnings Snapshot	AQ
03-31	Ziopharm: Q4 Earnings Snapshot	AQ
03-02	Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders	AQ

30/06/15	Alibaba : Les valeurs à suivre sur les marchés américains
30/06/15	USA-Les valeurs à suivre à Wall Street

1 day	+2.26%
1 week	-0.88%
Current month	-20.70%
1 month	-10.32%
3 months	-31.52%
6 months	-46.95%
Current year	-30.03%

1 week	1.92	2.33
1 month	1.92	3.09
Current year	1.92	4.04
1 year	1.67	6.2
3 years	1.31	79.59
5 years	1.31	601.5
10 years	1.31	1,182

Manager	Title	Age	Since
Holger Weis CEO	Chief Executive Officer	63	01/07/2025
Ferdinand Groenewald DFI	Director of Finance/CFO	41	21/02/2025

Director	Title	Age	Since
Jaime Vieser BRD	Director/Board Member	57	15/12/2020
Holger Weis CHM	Chairman	63	21/09/2023
Robert Postma BRD	Director/Board Member	72	04/02/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
05-21	Holger Weis	Free	Chief Executive Officer	3,700	0.1556%
04-28	Michael Jerman	Free	Director	6,032	0.2703%
04-28	Jaime Vieser	Free	Director	6,515	0.2919%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALAUNOS THERAPEUTICS, INC.	+2.26%	-0.88%	-26.50%	-96.72%	5.47M
ARGENX SE	+1.03%	+2.30%	+55.91%	+114.22%	56.42B
WUXI APPTEC CO., LTD.	+2.72%	+3.26%	+47.26%	+47.26%	44.54B
BIONTECH SE	+1.12%	+2.79%	-15.04%	-21.68%	22.9B
INSMED INCORPORATED	+1.17%	+3.85%	-0.89%	+403.86%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	+3.81%	-5.07%	+11.00%	-30.62%	16.4B
GENMAB A/S	+0.15%	+2.24%	+9.32%	-39.30%	15.4B
EXELIXIS, INC.	-0.69%	+0.82%	+27.75%	+176.72%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+5.27%	+5.54%	+19.65%	-	12.36B
PHARMAESSENTIA CORPORATION	+1.61%	+1.28%	+92.88%	+215.31%	11.15B
Average	+1.84%	+1.79%	+22.13%	+85.45%	21.37B
Weighted average by Cap.	+1.72%	+2.37%	+32.14%	+100.67%

	2024	2025
Net sales	0.01 0.01 0.01 0.01 0.01 0.95 0.01 0.09 0.04 0.46 0.04 0.04 1.6	0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.23 0.02 0.02 0.8
Net income	-4.68M -4.05M -3.73M -3.49M -6.55M -445M -6.64M -44.15M -17.18M -216M -17.56M -17.19M -750M	-4.18M -3.61M -3.33M -3.12M -5.84M -397M -5.93M -39.41M -15.33M -193M -15.67M -15.34M -669M
Net Debt	-1.09M -943K -869K -814K -1.53M -104M -1.55M -10.3M -4.01M -50.47M -4.09M -4.01M -175M	-1.38M -1.2M -1.1M -1.03M -1.94M -132M -1.97M -13.07M -5.09M -64.07M -5.2M -5.09M -222M